Bin Zhao

Dr. Bin Zhao

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2019 in Chemical Science
Verified
Journal Article
Open access
PDF file
YBYousef Bagheri
Yousef Bagheri
SCSara Chedid
Sara Chedid
FSFatemeh Shafiei
Fatemeh Shafiei
BZBin Zhao
Bin Zhao
Mingxu YouMingxu You
Mingxu You
A comprehensive and quantitative study of the dynamic process of lipid–DNA conjugate modification onto cell membranes.

11 June 2019 in BioMedical Engineering OnLine
Verified
Journal Article
Open access
PDF file
ASAlexander F. Smith
Alexander F. Smith
BZBin Zhao
Bin Zhao
Mingxu YouMingxu You
Mingxu You
JJJuan M. Jiménez
Juan M. Jiménez
Patients with end-stage renal disease (ESRD) have failed kidney function, and often must be treated with hemodialysis to extend the patient’s life by artificially removing excess fluid and toxins from the blood. However, life-threatening treatment complications can occur because hemodialysis protocols are adjusted infrequently, as opposed to the kidneys which filter blood continuously. Infrequent blood tests, about once per month on average, are used to adjust hemodialysis protocols and as a result, patients can experience electrolyte imbalances, which can contribute to premature patient deaths from treatment complications, such as sudden cardiac death. Since hemodialysis can lead to blood loss, drawing additional blood for tests to assess the patient’s kidney function and blood markers is limited. However, sampling multiple drops of blood per session using a microfluidic device has the potential to reduce not only the amount of blood drawn and avoid unnecessary venipuncture, but also reduce costs by limiting medical complications of hemodialysis and provide a more comprehensive assessment of the patient’s health status in real time. We present preliminary proof-of-concept results of a microfluidic device which uses DNA-based fluorescence nanosensors to measure potassium concentration in a flowing solution. In a matter of minutes, the flowing potassium solution reduced the fluorescence intensity of the nanosensors to a steady-state value. These proof-of-concept results demonstrate the ability of our DNA-based nanosensors to measure potassium concentration in a microfluidic device. The long-term goal is to integrate this technology with a device to measure potassium and eventually other blood contents multiple times throughout a hemodialysis session, enabling protocol adjustment similar to a healthy kidney.